Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors, following disappointing financial results for Q1 2025 that led to a significant drop in stock price [1][3]. Financial Performance - On May 8, 2025, Globus reported non-GAAP earnings per share of $0.68, which was $0.06 below consensus estimates [3]. - The company's revenue for Q1 2025 was $598.12 million, missing consensus estimates by $27.78 million and reflecting a 1.4% decline year-over-year [3]. - Following the announcement of these results, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Company Challenges - The decline in financial performance was attributed to softer deal closures in Enabling Technology, temporary supply chain disruptions related to integration, and the timing of international distributor orders [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors [1] Financial Performance - On May 8, 2025, Globus reported Q1 2025 financial results, with non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06 [2] - Revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [2] - The decline in performance was attributed to softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders [2] Market Reaction - Following the financial results announcement, Globus's stock price dropped by $16.64 per share, or 22.96%, closing at $55.82 per share on May 9, 2025 [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. following disappointing financial results for Q1 2025, which led to a significant drop in the company's stock price [1][3]. Financial Performance - Globus Medical reported non-GAAP earnings per share of $0.68 for Q1 2025, missing consensus estimates by $0.06 [3]. - The company's revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [3]. - Following the announcement of these results, Globus's stock price decreased by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Company Challenges - The decline in financial performance was attributed to several factors, including softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders [3].

Core Viewpoint - Globus Medical, Inc. has authorized a share repurchase program of up to $500 million to address the disconnect between its intrinsic value and market valuation, reflecting confidence in its long-term growth and profitability [1][2]. Group 1: Share Repurchase Program - The share repurchase program is aimed at buying back up to $500 million of the company's outstanding common stock [1]. - The timing and number of shares repurchased will be at management's discretion, influenced by market conditions and other factors [2]. - The program will be funded using the company's cash reserves and aligns with its long-term capital allocation strategy [3]. Group 2: Company Overview - Globus Medical is a leading global musculoskeletal solutions company focused on addressing unmet clinical needs and improving patient outcomes [4]. - The company emphasizes innovation, education, and clinical support across various areas including spine, orthopedic trauma, and joint reconstruction [4].

Company Overview - Outset Medical, Inc. is a medical technology company focused on pioneering technology to reduce the cost and complexity of dialysis [4] - The company's flagship product, the Tablo® Hemodialysis System, is FDA cleared for use from hospital to home, representing a significant advancement in dialysis technology [4] - Tablo integrates water purification and on-demand dialysate production, allowing it to function as a mobile dialysis clinic with 2-way wireless data transmission and a proprietary data analytics platform [4] Leadership Changes - Kevin O'Boyle has been appointed to the Board of Directors and as chair of the Audit Committee, bringing over 20 years of healthcare leadership experience [2][3] - O'Boyle's previous roles include CFO of several publicly traded companies and board director of six public medical device companies, which will aid Outset in its growth [2] - Dale E. Jones has stepped down from the Board, with appreciation expressed for his contributions during a critical period for the company [3]

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq. Admitted CA, NY and TX Bars lesley@portnoylaw.com 310-692-8883 www.portnoylaw.com Attorney Advertising On May 8, 2025, Globus issued a press release announcing its financial results for the first quarter of 2025. The Company reported non-G ...

Core Viewpoint - Globus Medical, Inc. reported disappointing first-quarter 2025 results, with both adjusted earnings per share (EPS) and revenues missing estimates, primarily due to lower sales in enabling technologies and supply chain disruptions [11][12]. Financial Performance - Adjusted EPS for Q1 2025 was 68 cents, missing the Zacks Consensus Estimate by 8.1%, but showing a year-over-year increase of 7.9% [1] - GAAP diluted EPS was 54 cents, a significant improvement from a loss of 5 cents per share in the same period last year [2] - Revenues decreased by 1.4% year over year to $598.1 million, missing the Zacks Consensus Estimate by 4.8% [3] Geographic Performance - U.S. net sales increased by 0.2% year over year to $483.9 million, falling short of the projected $519.2 million [4] - International revenues decreased by 7.7% to $114.3 million, also missing the estimate of $124.6 million [4] Product Performance - Musculoskeletal Solutions generated revenues of $575.9 million, up 0.2% year over year, but below the projected $597.1 million [5] - Enabling Technologies saw a significant decline in revenues, down 30.6% to $22.2 million, missing the estimate of $46.7 million [5] Margin Analysis - Gross profit rose by 10.3% year over year to $402.7 million, with gross margin expanding by 714 basis points to 67.3% due to a 19.1% decrease in the cost of sales [6] - Adjusted operating profit was $126.9 million, up 114.2% from the previous year, with an adjusted operating margin of 21.2%, an increase of 1145 basis points [7] Cash Position - The company ended Q1 2025 with cash and cash equivalents totaling $461.3 million, down from $890.1 million at the end of Q4 2024 [8] - Net cash provided by operating activities was $177.3 million, compared to $52.4 million in the prior year [9] Guidance - The company reaffirmed its full-year 2025 net sales guidance of $2.80-$2.90 billion, while lowering its adjusted EPS guidance to $3.00-$3.30 from $3.10-$3.40 [10]

Group 1: Market Overview - U.S. stock futures were higher, with Nasdaq futures gaining around 0.5% on Friday [1] Group 2: Company-Specific Performance - Expedia Group, Inc. reported Q1 revenue of $2.99 billion, a 3% year-over-year increase, but missed the consensus estimate of $3.01 billion, leading to a 9.8% drop in shares to $152.40 in pre-market trading [1] - Jade Biosciences, Inc. shares tumbled 44.4% to $5.00 in pre-market trading [4] - Iovance Biotherapeutics, Inc. shares dipped 35.6% to $2.04 after reporting worse-than-expected Q1 results [4] - Profound Medical Corp. fell 34.7% to $3.25 following downbeat quarterly earnings [4] - Globus Medical, Inc. tumbled 17.2% to $60.00 after reporting disappointing Q1 results and cutting FY25 adjusted EPS guidance [4] - FIGS, Inc. fell 16.2% to $4.22 after reporting Q1 results [4] - Wolfspeed, Inc. declined 13.2% to $3.84 after mixed quarterly results [4] - Onto Innovation Inc. dipped 11.6% to $112.00 after issuing a weak Q2 forecast [4] - OUTFRONT Media Inc. declined 7% to $14.31 following downbeat quarterly results [4] - Grindr Inc. dipped 6.7% to $22.80 after reporting worse-than-expected quarterly sales [4] - Affirm Holdings, Inc. dipped 6.3% to $50.82 following third-quarter results [4] - HubSpot, Inc. fell 4.7% to $629.00 after reporting Q1 results and issuing second-quarter adjusted EPS guidance below estimates [4]

Core Viewpoint - Globus Medical reported a decline in net sales for Q1 2025, attributed to multiple factors including slowed technology transactions, supply chain disruptions, and fluctuations in international distributor orders, although the core U.S. spine business performed well [4][6]. Financial Performance - For Q1 2025, Globus Medical's global net sales were $598.1 million (approximately 4.3 billion RMB), a year-over-year decrease of 1.4%. On a constant currency basis, the decline was 0.8% [6]. - The GAAP net income for the quarter was $75.5 million, with a GAAP diluted earnings per share (EPS) of $0.54 and a non-GAAP diluted EPS of $0.68 [6]. - The company generated a record free cash flow of $141.2 million during the quarter and reaffirmed its full-year revenue guidance of $2.8 to $2.9 billion, while updating its non-GAAP EPS guidance to a range of $3.00 to $3.30 [6]. Mergers and Acquisitions - In February 2023, Globus Medical announced a $3.1 billion (approximately 21.1 billion RMB) acquisition of NuVasive, with NuVasive shareholders owning about 28% of the combined company post-transaction [4][7]. - The acquisition of Nevro for approximately $250 million was announced in early 2025, with a premium of 27% over Nevro's average stock price over the past 90 days [9][11]. Strategic Developments - The merger with NuVasive is expected to enhance the combined company's capabilities in the $50 billion global market for spine and orthopedic technologies, with analysts praising the integration as one of the most successful in the spine industry [7]. - The company launched 18 new products in 2024, including innovations that leverage the strengths of both companies, such as the ExcelsiusHub robotic platform integrated with Pulse neuro-monitoring technology [13]. Leadership Changes - In February 2025, the company announced that President Anthony L. Williams would leave by May 31, 2025, with CEO Dan Scavilla temporarily taking over the role to ensure operational stability during the transition [8].

Core Viewpoint - Globus Medical reported a decline in revenue and earnings for the quarter ended March 2025, missing Wall Street expectations, indicating potential challenges in financial performance [1][2]. Financial Performance - Revenue for the quarter was $598.12 million, down 1.4% year-over-year, and below the Zacks Consensus Estimate of $628.32 million by 4.81% [1]. - Earnings per share (EPS) were $0.68, a decrease from $0.72 in the same quarter last year, and fell short of the consensus estimate of $0.74 by 8.11% [1]. Geographic Revenue Breakdown - International revenue was reported at $114.26 million, which is 7.7% lower than the three-analyst average estimate of $127.52 million [4]. - U.S. revenue stood at $483.86 million, slightly up by 0.2% year-over-year, but below the average estimate of $510.72 million [4]. Product Category Performance - Net sales from Enabling Technologies were $22.19 million, significantly lower than the estimated $38.79 million, reflecting a year-over-year decline of 30.6% [4]. - Musculoskeletal Solutions generated $575.93 million in sales, which was marginally above the year-ago figure by 0.2%, but still below the estimated $598.85 million [4]. Stock Performance - Shares of Globus Medical have returned -3.7% over the past month, contrasting with the Zacks S&P 500 composite's increase of 11.3% [3]. - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3].